Unlocking The Potential For a Better Life


Medlab Clinical LTD (ASX.MDC) is an Australian based publicly listed biotechnology company with a portfolio of novel medicine candidates enhanced by its patented medicine delivery platform NanoCelle®.

NanoCelle® is wholly owned by Medlab Clinical and is used to enhance a wide range of active ingredients, with commercial opportunities in pharmaceuticals, generic medicines, cosmetics, nutraceuticals, and textiles. This pioneering delivery platform allows for the development and commercialisation of new products with enhanced medical properties, including increased efficacy, safety, patient compliance and stability. NanoCelle® underpins our growth strategy by offering near-term partnering opportunities whilst enhancing our pharma portfolio.

Medlab’s products are proudly validated by research and supported by a growing patent portfolio. Our team of scientists, researchers and doctors are dedicated to building products that are scientifically optimised to deliver more for human health and beyond. Our pipeline comprises both small and large molecules ranging from repurposing generic medicines to enhancing the delivery of immunotherapies.

Investment Highlights

  • Patented NanoCelle® drug delivery platform with value creation optionality, enhancing our product portfolio whilst offering near term partnering opportunities
  • World-class Board, management and scientific consulting team with strong experience bringing novel therapeutics to market
  • Scientifically optimised portfolio of cannabinoid therapeutics addressing a global unmet need in oncology areas including pain management
  • Lead candidate NanaBis™ Phase I/II primary and secondary endpoints met in bone cancer patients, replicated in a real-world observational study. Stage III commencing in near-term with robust and clear drug pathway in US, EU and Australia
  • NanaBis™ proof of concept established and early revenue being generated via Special Access Scheme

Have a question?

Investor Inquiries: Laine Yoker, Medlab US Investor Relations, [email protected]  

General Inquiries: [email protected]




Have an investor relationship question, you can book a meeting with our CEO, Dr Sean Hall





Schedule a meeting

Sign up for Investor Updates


Stay up-to-date with the latest investor news, presentations and videos from Medlab sent directly to your email address.


* indicates required

Latest Investor News

Now this is scalable – a drug delivery platform rather than a drug itself

Now this is scalable – a drug delivery platform rather than a drug itself

Listen to ASX-listed Medlab Clinical CEO Dr Sean Hall talk to Matt Birney on the Bulls N’ Bears Report on Deb Knight show on 873 am. (2GB), about Medlab’s development of a potent drug delivery platform that can potentially piggyback any drug to where it needs to go.


Medlab Clinical Ltd (ASX:MDC) sells its nutraceutical business to PharmaCare

Medlab Clinical Ltd (ASX:MDC) sells its Australian nutraceutical business to PharmaCare

We would like to inform you that Medlab Clinical Ltd (ASX:MDC) is very pleased to announce the sale of the Australian-only part of its nutraceutical business to PharmaCare, a well-established and respected Australian health & wellness company.


Annual Message to Shareholders October 2021

Annual Message to Shareholders October 2021

Medlab Confirms US Patent Office has approved NanoCelle® patent for USA territories this is in addition to the receipt of a further 42 worldwide patents.


Edison Group – Executive interview with CEO, Dr Sean Hall

In this video, Dr Sean Hall, Medlab’s co-founder and CEO, introduces us to Medlab and its lead programmes and discusses what we can expect from this fast-growing company over the coming months.


Medlab Clinical talks upcoming Phase III NanaBis trial and NanoCelle partnering opportunities

Medlab Clinical Ltd's (ASX:MDC) Dr Sean Hall tells Proactive's Andrew Scott they're focused on achieving regulatory approval for its lead drug candidate NanaBis™ in the shortest time possible. He adds that they've identified multiple revenue-generating partnering opportunities for its NanoCelle® drug delivery platform which he says can improve the efficacy of multiple medicines and therapeutics.


Jefferies Healthcare Conference - 2021

Medlab outlines its growth strategy for US and global investors at the prestigious annual Jefferies Healthcare Conference.


Small Caps interview of CEO Sean Hall

Small Caps interviews the CEO of Medlab, Sean Hall about the future of NanoCelle® drug delivery technology and pharmaceutical portfolio


Medlab Clinical and microsoft mixed reality hololens 2

Medlab mixes reality with Microsoft

Read the three featured stories from Microsoft about Medlab's adoption of mixed reality solutions including HoloLens 2 head-mounted devices with Dynamics 365 Remote Assist, to help combat the pandemic by improving time to market and guaranteeing crucial business progression.


NanaBis improvement in pain scores observational study

NanaBis demonstrates continued improvement in pain scores

The first cohort of Observational Study patients completing 12-month treatment with NanaBis™ demonstrated continued improvement in pain scores.


Medlab Clinical to be granted European patent for NanoCelle drug delivery platform

Medlab to be granted European patent for NanoCelle® drug delivery platform

European Patent Office issues Notice of Intention to grant Medlab Clinical patent for NanoCelle® drug delivery platform


Novartis Managing Director of Oncology (ANZ/NZ) appointed to board of Medlab Clinical

Novartis’ Managing Director of Oncology (ANZ/NZ) joins Medlab Clinical board

Medlab Clinical appoints Novartis' Managing Director of Oncology for Australia and New Zealand as Non-Executive Director.


Medlab Clinical Raises Cash for phase 3 clinical trial and Leading Novartis Executive Joins Board

Medlab Clinical raises $15 million and Leading Executive Joins Board

Medlab Clinical successfully raised $15 million to help fund its upcoming Phase III clinical trial and has extended its board expertise with the appointment of leading pharmaceutical executive Mrs Cheryl Maley.


Medlab Clinical equity injection

Medlab Clinical looks for $15 million equity injection

Medlab clinical looks to raise $15 million to fund its Phase III trial. Read more here.


Medlab Clinical partners with Arrotex

Medlab Clinical partners with Arrotex

Medlab Clinical partners with Arrotex to accelerate NanoCBD availability in Australian pharmacies


Medlab Clinical to confirm NanaBis’ potential as non-opioid pain treatment in phase three trials

Medlab to confirm NanaBis’ potential as non-opioid analgesic in phase III trial

Read the write up from Small Caps about Medlab's non-opioid pain treatment


Ausbiz interview of CEO Sean Hall

Ausbiz interviews the CEO of Medlab, Sean Hall about the future of Medlab


Ausbiz interview

Ausbiz interviews the CEO of Medlab, Sean Hall about the future of Medlab


Switzer Investor Day

4th Small and Micro-Cap Virtual Investor Day


Nanabis Presentation

Nanabis Presentation

Learn more about NanaBis and the significant opportunity ahead


StockPal Webinar

StockPal Webinar

In this part two of a four-part webinar recap, Sean Hall, Chief Executive Officer and Managing Director of Medlab (ASX:MDC) presented on the company’s latest announcements and updates while answering some questions during the Q&A session at the end.